Gallstone Disease and Bacterial Metabolic Performance of Gut Microbiota in Middle-Aged and Older Patients.
biliary calculi
dysbiosis
intestinal functional bacteria
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
12
2021
accepted:
16
05
2022
entrez:
15
6
2022
pubmed:
16
6
2022
medline:
16
6
2022
Statut:
epublish
Résumé
Gallstone disease (GSD) is more commonly presented in aged people. The purpose of the study was to explore the insights of metabolic performance of bacterial species from gut microbiota as well as the clinical background in middle-aged and elderly patients with GSD. This is an observational study concerning 120 research participants. Of those, 90 patients with symptomatic GSD addressed for cholecystectomy, average age 59.83 ± 15.32 years: 45 with cholesterol rich gallstones (CGSs), 45 with pigment gallstones (PGSs) and 30 healthy controls joined this observational study. Clinical examination, lab work-ups, upper and lower digestive video-endoscopies, abdominal ultrasound/CT and gallbladder motility assessment by Dodd's method were performed. Overall stool dysbiosis (DB) was assessed as 1 = minor, 2 = mild, 3 = severe, species being identified by matrix-assisted laser desorption ionization method. Stool samples from dysbiotic patients were analyzed by a next generation sequencing method with operational taxonomic unit identification. Patients with GSD presented with a significant high range of overall gut DB (p < 0.0001) when compared with controls. Those with CGSs compared with those having PGSs displayed significant clinical differences related to elderly age, lifestyle and diet particularities, obesity, dyslipidemia, nonalcoholic fatty liver disease, hypertension, type 2 diabetes mellitus or impaired glucose tolerance, as well as motility disturbances of gallbladder with a decrease of the ejection fraction. Significant increase of overall DB range and alterations of several functional bacterial species with a decrease of butyrate, lactate, acetate/propionate and methane producers, mucin degrading bacteria, biodiversity index of microbiota, as well as an increase of lipopolysaccharide positive bacteria were significantly present in patients with CGSs. Middle-aged and elderly patients with GSD and a clinical background characterized by particular lifestyle, metabolic and gallbladder motility issues displayed significant modifications of biodiversity, overall gut DB and alterations of several functional bacterial species, with a decrease of their metabolic performance.
Sections du résumé
Background
UNASSIGNED
Gallstone disease (GSD) is more commonly presented in aged people.
Purpose
UNASSIGNED
The purpose of the study was to explore the insights of metabolic performance of bacterial species from gut microbiota as well as the clinical background in middle-aged and elderly patients with GSD.
Patients and Methods
UNASSIGNED
This is an observational study concerning 120 research participants. Of those, 90 patients with symptomatic GSD addressed for cholecystectomy, average age 59.83 ± 15.32 years: 45 with cholesterol rich gallstones (CGSs), 45 with pigment gallstones (PGSs) and 30 healthy controls joined this observational study. Clinical examination, lab work-ups, upper and lower digestive video-endoscopies, abdominal ultrasound/CT and gallbladder motility assessment by Dodd's method were performed. Overall stool dysbiosis (DB) was assessed as 1 = minor, 2 = mild, 3 = severe, species being identified by matrix-assisted laser desorption ionization method. Stool samples from dysbiotic patients were analyzed by a next generation sequencing method with operational taxonomic unit identification.
Results
UNASSIGNED
Patients with GSD presented with a significant high range of overall gut DB (p < 0.0001) when compared with controls. Those with CGSs compared with those having PGSs displayed significant clinical differences related to elderly age, lifestyle and diet particularities, obesity, dyslipidemia, nonalcoholic fatty liver disease, hypertension, type 2 diabetes mellitus or impaired glucose tolerance, as well as motility disturbances of gallbladder with a decrease of the ejection fraction. Significant increase of overall DB range and alterations of several functional bacterial species with a decrease of butyrate, lactate, acetate/propionate and methane producers, mucin degrading bacteria, biodiversity index of microbiota, as well as an increase of lipopolysaccharide positive bacteria were significantly present in patients with CGSs.
Conclusion
UNASSIGNED
Middle-aged and elderly patients with GSD and a clinical background characterized by particular lifestyle, metabolic and gallbladder motility issues displayed significant modifications of biodiversity, overall gut DB and alterations of several functional bacterial species, with a decrease of their metabolic performance.
Identifiants
pubmed: 35702368
doi: 10.2147/IJGM.S350104
pii: 350104
pmc: PMC9188808
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5513-5531Informations de copyright
© 2022 Georgescu et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Medicina (Kaunas). 2019 Dec 16;55(12):
pubmed: 31888137
Immunology. 2017 Aug;151(4):363-374
pubmed: 28542929
Acta Cir Bras. 2019 Feb 14;34(1):e20190010000009
pubmed: 30785510
J Gastroenterol Hepatol. 2014 Aug;29(8):1614-9
pubmed: 24628028
Hepatobiliary Pancreat Dis Int. 2021 Feb;20(1):61-66
pubmed: 33341401
Eur J Prev Cardiol. 2015 Mar;22(3):326-34
pubmed: 24177267
Nutrients. 2019 Nov 07;11(11):
pubmed: 31703257
Hepatology. 2016 Mar;63(3):764-75
pubmed: 26600078
Gastroenterology. 2019 Jul;157(1):97-108
pubmed: 30940523
Environ Microbiol Rep. 2015 Dec;7(6):874-80
pubmed: 26149537
BMC Gastroenterol. 2017 Jun 9;17(1):74
pubmed: 28599622
Circulation. 2004 Jul 13;110(2):227-39
pubmed: 15249516
Cell Metab. 2013 Feb 5;17(2):225-35
pubmed: 23395169
Curr Opin Microbiol. 2013 Jun;16(3):255-61
pubmed: 23831042
ISME J. 2017 Jul;11(7):1667-1679
pubmed: 28375212
Br J Pharmacol. 2018 Feb;175(3):469-484
pubmed: 29139555
Front Physiol. 2021 Aug 19;12:716654
pubmed: 34489732
J Med Microbiol. 2021 Oct;70(10):
pubmed: 34623232
Gastroenterology. 2021 May;160(6):2029-2042.e16
pubmed: 33482223
BMC Gastroenterol. 2020 Mar 6;20(1):59
pubmed: 32143645
Eur J Nutr. 2018 Feb;57(1):1-24
pubmed: 28393285
Front Microbiol. 2018 Jan 30;9:61
pubmed: 29441049
J Clin Med. 2019 Jan 11;8(1):
pubmed: 30641967
Int J Womens Health. 2022 Jan 26;14:41-56
pubmed: 35136356
Viszeralmedizin. 2015 Jun;31(3):156-61
pubmed: 26468308
Biomed Res Int. 2020 Jul 01;2020:1242364
pubmed: 32714973
AJR Am J Roentgenol. 1985 Nov;145(5):1009-11
pubmed: 3901703
Gut Liver. 2012 Apr;6(2):172-87
pubmed: 22570746
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Clin Liver Dis (Hoboken). 2021 Feb 01;17(1):15-18
pubmed: 33552480
Gut Microbes. 2020 Nov 9;12(1):1785251
pubmed: 32684075
Diabetes Care. 2014 Jan;37 Suppl 1:S81-90
pubmed: 24357215
J Cell Mol Med. 2019 Apr;23(4):2343-2350
pubmed: 30712327
Curr Opin Gastroenterol. 2013 Jan;29(1):49-54
pubmed: 23041677
Curr Opin Gastroenterol. 2018 Mar;34(2):71-80
pubmed: 29283909
PLoS One. 2013 Oct 04;8(10):e74887
pubmed: 24124459
Curr Opin Gastroenterol. 2014 May;30(3):332-8
pubmed: 24625896
Hepatology. 2020 Mar;71(3):893-906
pubmed: 31298745
Acta Biochim Biophys Sin (Shanghai). 2020 Feb 3;52(2):200-206
pubmed: 31915810
Appl Microbiol Biotechnol. 2021 Jun;105(12):4833-4841
pubmed: 34125276
J Food Drug Anal. 2019 Apr;27(2):404-414
pubmed: 30987712
Int J Obes Suppl. 2019 Apr;9(1):10-19
pubmed: 31391921
Yonsei Med J. 2003 Aug 30;44(4):561-70
pubmed: 12950109
BMC Genomics. 2013 Oct 01;14:669
pubmed: 24083370
Am J Epidemiol. 2014 Mar 15;179(6):731-9
pubmed: 24470530
Microbiome. 2019 Jul 4;7(1):100
pubmed: 31272480
Best Pract Res Clin Gastroenterol. 2006;20(6):1017-29
pubmed: 17127185
J Gastroenterol. 2017 Mar;52(3):276-300
pubmed: 27942871
Lancet. 2006 Jul 15;368(9531):230-9
pubmed: 16844493
Microorganisms. 2020 Jun 02;8(6):
pubmed: 32498344
World J Gastroenterol. 2014 Nov 21;20(43):16079-94
pubmed: 25473159
Gastroenterol Hepatol Bed Bench. 2019;12(Suppl1):S8-S13
pubmed: 32099595
World J Gastroenterol. 2016 Jun 14;22(22):5201-10
pubmed: 27298563
J Lipid Res. 2012 Oct;53(10):2231-2241
pubmed: 22822028
Prev Nutr Food Sci. 2020 Jun 30;25(2):113-123
pubmed: 32676461
Practitioner. 2015 Jun;259(1783):15-9, 2
pubmed: 26455113
J Intensive Care Med. 2016 Jan;31(1):3-13
pubmed: 25320159
Gut. 2020 Dec;69(12):2232-2243
pubmed: 32917747
Rom J Morphol Embryol. 2019;60(1):205-210
pubmed: 31263846
Medicina (Kaunas). 2019 Jun 25;55(6):
pubmed: 31242663
Gut Microbes. 2016 May 3;7(3):201-15
pubmed: 27003186
Gut Microbes. 2020;11(2):158-171
pubmed: 31595814
Front Genet. 2015 Jun 23;6:219
pubmed: 26157455
Best Pract Res Clin Gastroenterol. 2006;20(6):981-96
pubmed: 17127183
J Clin Med. 2017 Oct 26;6(11):
pubmed: 29072609